National Cancer Center Hospital East

This study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…

This phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to se…

This early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to …

This Phase 3 study tested the drug FTD/TPI (a chemotherapy pill) against a placebo in 243 people who had surgery for colorectal cancer but still had cancer DNA in their blood. The goal was to see if the drug could prevent the cancer from coming back. Participants took the drug or…